Oct 22, 2026 · 44 min
AI Sell-Off Tests Tech’s Growth Story
Tech Tumbles In Market Sell-Off… And Moderna’s Meltdown After Data Leak 10/22/26
The episode weighs whether falling technology stocks signal a temporary risk repricing or deeper doubts about AI financing, monetization, and economic growth.
- 1AI’s capital-intensive buildout faces tougher scrutiny as expensive financing collides with uncertain monetization and data-center risks.
- 2Falling rates create selective opportunities in housing and utilities, even as investors debate whether the economy is slowing.
- 3Moderna’s leaked cancer-vaccine data triggered a stock collapse, while options trading pointed to continued volatility and competing rebound bets.
Don't miss
Moderna’s stock plunge after leaked cancer-vaccine data is reassessed when the subsequently released results broadly meet expectations, while options signal more volatility.
The brief
A tech-led sell-off puts the AI trade on trial: investors are questioning expensive debt, data-center spending, capital constraints, and whether uncertain monetization can justify the buildout.
The panel frames the decline as a possible repricing of risk rather than a fundamental crisis, while weighing hyperscalers against hardware suppliers and utilities as an AI-adjacent opportunity.
Lower Treasury yields revive housing stocks, but the discussion separates durable demand from a reflexive rally, with selective interest in homebuilders such as D.R. Horton.
Moderna’s shares plunge after cancer-vaccine results leak online, then recover some context when the released data broadly meet expectations; heavy put buying keeps the volatility debate alive.
The episode widens its lens to Iran-related oil risk, possible SpaceX pressure on telecom, luxury weakness at Kering, and Apple’s roughly $2,000 foldable iPhone launch.
The closing trades return to the central question: where can investors find opportunity when falling rates, earnings surprises, and AI uncertainty are reshaping market leadership?
What was said on this episode
40 statements · 19 positive · 18 negative · 1 mixed · 2 neutral
Neocloud demand is exceptionally strong and their capabilities are extraordinary.
“The demand for the neoclouds is off the charts. Their capabilities are extraordinary.”
Listen at 1:36
Meta must monetize Muse while operating cash flow has turned negative.
“they're going to have to monetize this muse. They are now cash flow negative for the first time in a decade.”
Listen at 2:32
Companies will face more expensive debt or equity financing.
“Companies are going to have to issue more expensive capital, which is either higher cost debt or equity”
Listen at 3:33
Some companies will be unable to obtain capital.
“some companies won't get capital.”
Listen at 3:42
Financial conditions are tightening rapidly.
“Our financial conditions are being tightened by the second.”
Listen at 4:29
Markets are pricing a growth scare rather than a credit scare.
“markets are sniffing out a growth scare. They're not sniffing out a credit scare.”
Listen at 4:57
The current equity-market problem is primarily a growth scare.
“I think right now it's more of a growth scare for equities”
Listen at 5:50
Stocks are not priced for slower growth.
“I don't think stocks are priced for less growth here.”
Listen at 5:59
Data-center opposition rhetoric will diminish after the midterms.
“if you can get past the midterms, that rhetoric dies down.”
Listen at 6:49
The economy is still growing.
“We still are in a growing economy.”
Listen at 6:58
Anthropic and OpenAI revenue growth is decelerating.
“there's some deceleration in revenue.”
Listen at 8:17
The AI trade is not over.
“I don't think this trade is over.”
Listen at 9:06
Interest rates will continue rising.
“rates, although I still think are going higher”
Listen at 11:04
“you could have a back and fill to 485. We'll stand by that because I think that's where it probably goes.”
Listen at 11:07
Data-center controversy and rhetoric will subside after elections.
“once we get through the elections, the data center issue and the rhetoric will die down.”
Listen at 14:36
Hyperscalers are preferable to Nvidia.
“I'd rather be in hyperscalers.”
Listen at 16:02
Investors should move beyond AI hardware suppliers.
“I think it's time to move on from the picks and the shovels.”
Listen at 16:09
Hyperscalers will retain ample capacity to issue needed debt.
“hyperscalers, I think they'll have plenty of ability to issue whatever they need as we go forward in time.”
Listen at 17:00
Utilities can provide both defensive and offensive exposure.
“I think the utilities can also play offense and defense”
Listen at 17:47
Utilities are attractive investments.
“We like the utility space.”
Listen at 18:11
Investors should not chase staples because valuations are expensive.
“I don't think you want to chase any staples companies here. None of them are cheap.”
Listen at 19:33
The staples rally will not last, so investors should avoid buying staples.
“I don't think either one of them are going to last, so I wouldn't be a buyer of Staples right now.”
Listen at 20:05
Some interest-rate-sensitive stocks may be worth owning short term.
“I think in the short term, I think there's a chance to own some of the stuff.”
Listen at 21:35
Homebuilder performance reflects economic slowing more than interest rates.
“I don't think it's about interest rates. I think it's about an economy that seemingly is slowing.”
Listen at 22:37
Investors should avoid homebuilders in a slowing, stagflationary economy.
“You don't own homebuilders in that environment.”
Listen at 22:42
Investors should begin cautiously buying D.R. Horton.
“So I would probably start to dip a toe.”
Listen at 23:07
Gold miners are undervalued at gold prices near $4,000 per ounce.
“The miners at $4,000 an ounce, if you want to do that math, they're worth a lot more than they're priced here.”
Listen at 24:28
Moderna’s cancer-vaccine data were not poor.
“I actually don't think the data were bad at all.”
Listen at 26:58
Moderna and BioNTech dominate the near-term cancer-vaccine race.
“it's really just a two-horse race, I think, over the near term at least.”
Listen at 27:41
The trial provided no clear evidence for renal-cell or lung tumors.
“I'm not sure we learned anything about renal cell. And I'm not sure we learned anything about lung. So we're just going to have to wait.”
Listen at 28:35
Moderna is too volatile to trade currently.
“this Moderna is a do not trade type of stock because it's just so volatile.”
Listen at 28:43
Merck is attractive for investors bullish on the cancer-vaccine prospects.
“Merck is actually somewhat compelling here, I think, if you're actually bullish on the prospects.”
Listen at 28:48
Pharmaceutical stocks currently trade at higher valuations than large-cap technology stocks.
“Pharma stocks are now more expensive than traditional large cap tech stocks.”
Listen at 29:29
The healthcare sector is not attractive after recent fund inflows.
“I'm not that bullish on anything today”
Listen at 29:58
Investors should wait to buy AbbVie at a lower price.
“I would just love to buy it cheaper.”
Listen at 31:28
Investors should continue owning Bristol-Myers and Pfizer.
“I actually think that Bristol-Myers, Pfizer are ones you want to continue to own.”
Listen at 32:12
Investors should buy telecom weakness caused by SpaceX headlines.
“whenever you get some weakness in these names due to a SpaceX headline, you should probably try to buy that weakness.”
Listen at 34:44
Investors should own Northrop Grumman and Lockheed Martin.
“I think you've got to—Northrop, Lockheed, I think you've got to own both of those names.”
Listen at 35:32
The speaker owns Unilever but not Procter & Gamble.
“I'm actually long Unilever, but not Procter.”
Listen at 36:47
Louis Vuitton is preferable within the luxury sector.
“I'd rather, if I could, be in Louis Vuitton. So I think a better portfolio.”
Listen at 37:43
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Weekly email
State of the Pod, every Monday
The week's most-discussed names and stories from podcasts, with the moments behind them. Free, five minutes, unsubscribe in one click.